- Home
- AQST vs SABA Comparison
AQST vs SABA Comparison
Compare AQST & SABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AQST
- SABA
- Stock Information
- Founded
- AQST 2004
- SABA 1988
- Country
- AQST United States
- SABA United States
- Employees
- AQST N/A
- SABA N/A
- Industry
- AQST Biotechnology: Pharmaceutical Preparations
- SABA
- Sector
- AQST Health Care
- SABA
- Exchange
- AQST Nasdaq
- SABA Nasdaq
- Market Cap
- AQST 254.1M
- SABA 233.0M
- IPO Year
- AQST 2018
- SABA N/A
- Fundamental
- Price
- AQST $2.79
- SABA $8.62
- Analyst Decision
- AQST Strong Buy
- SABA
- Analyst Count
- AQST 5
- SABA 0
- Target Price
- AQST $11.40
- SABA N/A
- AVG Volume (30 Days)
- AQST 939.1K
- SABA 290.0K
- Earning Date
- AQST 05-12-2025
- SABA 01-01-0001
- Dividend Yield
- AQST N/A
- SABA 12.91%
- EPS Growth
- AQST N/A
- SABA N/A
- EPS
- AQST N/A
- SABA N/A
- Revenue
- AQST $57,561,000.00
- SABA N/A
- Revenue This Year
- AQST N/A
- SABA N/A
- Revenue Next Year
- AQST $39.51
- SABA N/A
- P/E Ratio
- AQST N/A
- SABA N/A
- Revenue Growth
- AQST 13.79
- SABA N/A
- 52 Week Low
- AQST $2.20
- SABA $3.64
- 52 Week High
- AQST $5.80
- SABA $4.42
- Technical
- Relative Strength Index (RSI)
- AQST 49.93
- SABA 52.34
- Support Level
- AQST $2.59
- SABA $8.52
- Resistance Level
- AQST $3.05
- SABA $8.84
- Average True Range (ATR)
- AQST 0.16
- SABA 0.19
- MACD
- AQST 0.00
- SABA 0.04
- Stochastic Oscillator
- AQST 43.57
- SABA 70.68
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
About SABA Saba Capital Income & Opportunities Fund II Shares of Beneficial Interest
Saba Capital Income & Opportunities Fund II is a closed-end fund. The company seeks high current income, with a secondary goal of capital appreciation. The fund invests in fixed income markets across the globe.